CAR-NK cells: the next wave of cellular therapy for cancer

被引：89

作者：

Daher, May ^{[1
]}

Garcia, Luciana Melo ^{[1
]}

Li, Ye ^{[1
]}

Rezvani, Katayoun ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, 1515 Holcombe Blvd,Unit 423, Houston, TX 77030 USA

来源：

CLINICAL & TRANSLATIONAL IMMUNOLOGY | 2021年 / 10卷 / 04期

关键词：

allogeneic; cancer immunotherapy; CAR; cellular therapy; NK cells; off-the-shelf product; CHIMERIC ANTIGEN RECEPTOR; NK-92; EXPRESSION; RESISTANCE; CD19;

D O I：

10.1002/cti2.1274

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

T cells engineered to express chimeric antigen receptors (CARs) have revolutionised the field of cellular therapy for cancer. Despite its success, this strategy has some recognised limitations and toxicities. Hence, there is growing interest in developing novel cellular therapies based on non-alpha beta T-cell immune effector cells, including NK cells that offer clear advantages in cancer immunotherapy. As a result, NK cells are being explored as an alternative platform for CAR engineering and are becoming recognised as important players in the next generation of cellular therapies targeting cancer. In this review, we highlight preclinical and clinical studies of CAR-NK cells derived from different sources and discuss strategies under investigation to enhance the antitumor activity of these engineered innate immune cells.

引用

页数：16

共 92 条

[41] GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells [J].

Liu, Enli ;

Ang, Sonny O. T. ;

Kerbauy, Lucila ;

Basar, Rafet ;

Kaur, Indreshpal ;

Kaplan, Mecit ;

Li, Li ;

Tong, Yijiu ;

Daher, May ;

Ensley, Emily L. ;

Uprety, Nadima ;

Nunez Cortes, Ana Karen ;

Yang, Ryan Z. ;

Li, Ye ;

Shaim, Hila ;

Reyes Silva, Francia ;

Lin, Paul ;

Mohanty, Vakul ;

Acharya, Sunil ;

Shanley, Mayra ;

Muniz-Feliciano, Luis ;

Banerjee, Pinaki P. ;

Chen, Ken ;

Champlin, Richard E. ;

Shpall, Elizabeth J. ;

Rezvani, Katayoun .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[42] Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors [J].

Liu, Enli ;

Marin, David ;

Banerjee, Pinaki ;

Macapinlac, Homer A. ;

Thompson, Philip ;

Basar, Rafet ;

Kerbauy, Lucila Nassif ;

Overman, Bethany ;

Thall, Peter ;

Kaplan, Mecit ;

Nandivada, Vandana ;

Kaur, Indresh ;

Cortes, Ana Nunez ;

Cao, Kai ;

Daher, May ;

Hosing, Chitra ;

Cohen, Evan N. ;

Kebriaei, Partow ;

Mehta, Rohtesh ;

Neelapu, Sattva ;

Nieto, Yago ;

Wang, Michael ;

Wierda, William ;

Keating, Michael ;

Champlin, Richard ;

Shpall, Elizabeth J. ;

Rezvani, Katayoun .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (06) :545-553

[43] Specific growth inhibition of ErbB2-expressing human breast cancer cells by genetically modified NK-92 cells [J].

Liu, Hui ;

Yang, Bo ;

Sun, Tingting ;

Lin, Lin ;

Hu, Yi ;

Deng, Muhong ;

Yang, Junlan ;

Liu, Tianyi ;

Li, Jinyu ;

Sun, Shengjie ;

Jiao, Shunchang .

ONCOLOGY REPORTS, 2015, 33 (01) :95-102

[44] Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor [J].

Liu, Yan ;

Zhou, Yehui ;

Huang, Kuo-Hsiang ;

Fang, Xujie ;

Li, Ying ;

Wang, Feifei ;

An, Li ;

Chen, Qingfei ;

Zhang, Yunchao ;

Shi, Aihua ;

Yu, Shuang ;

Zhang, Jingzhong .

CELL PROLIFERATION, 2020, 53 (08)

[45] Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial [J].

Locke, Frederick L. ;

Ghobadi, Armin ;

Jacobson, Caron A. ;

Miklos, David B. ;

Lekakis, Lazaros J. ;

Oluwole, Olalekan O. ;

Lin, Yi ;

Braunschweig, Ira ;

Hill, Brian T. ;

Timmerman, John M. ;

Deol, Abhinav ;

Reagan, Patrick M. ;

Stiff, Patrick ;

Flinn, Ian W. ;

Farooq, Umar ;

Goy, Andre ;

McSweeney, Peter A. ;

Munoz, Javier ;

Siddiqi, Tanya ;

Chavez, Julio C. ;

Herrera, Alex F. ;

Bartlett, Nancy L. ;

Wiezorek, Jeffrey S. ;

Navale, Lynn ;

Xue, Allen ;

Jiang, Yizhou ;

Bot, Adrian ;

Rossi, John M. ;

Kim, Jenny J. ;

Go, William Y. ;

Neelapu, Sattva S. .

LANCET ONCOLOGY, 2019, 20 (01) :31-42

[46] The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation [J].

Luevano, Martha ;

Daryouzeh, Mehri ;

Alnabhan, Rehab ;

Querol, Sergio ;

Khakoo, Salim ;

Madrigal, Alejandro ;

Saudemont, Aurore .

HUMAN IMMUNOLOGY, 2012, 73 (03) :248-257

[47] Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia [J].

Maude, S. L. ;

Laetsch, T. W. ;

Buechner, J. ;

Rives, S. ;

Boyer, M. ;

Bittencourt, H. ;

Bader, P. ;

Verneris, M. R. ;

Stefanski, H. E. ;

Myers, G. D. ;

Qayed, M. ;

De Moerloose, B. ;

Hiramatsu, H. ;

Schlis, K. ;

Davis, K. L. ;

Martin, P. L. ;

Nemecek, E. R. ;

Yanik, G. A. ;

Peters, C. ;

Baruchel, A. ;

Boissel, N. ;

Mechinaud, F. ;

Balduzzi, A. ;

Krueger, J. ;

June, C. H. ;

Levine, B. L. ;

Wood, P. ;

Taran, T. ;

Leung, M. ;

Mueller, K. T. ;

Zhang, Y. ;

Sen, K. ;

Lebwohl, D. ;

Pulsipher, M. A. ;

Grupp, S. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (05) :439-448

[48] Relapsed T Cell ALL: Current Approaches and New Directions [J].

McMahon, Christine M. ;

Luger, Selina M. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (02) :83-93

[49] CAR T cell therapies for patients with multiple myeloma [J].

Mikkilineni, Lekha ;

Kochenderfer, James N. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (02) :71-84

[50] CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview [J].

Mohty, Mohamad ;

Dulery, Remy ;

Gauthier, Jordan ;

Malard, Florent ;

Brissot, Eolia ;

Aljurf, Mahmoud ;

Bazarbachi, Ali ;

Chabanon, Christian ;

Kharfan-Dabaja, Mohamed A. ;

Savani, Bipin N. ;

Huang, He ;

Kenderian, Saad S. ;

Perales, Miguel-Angel ;

Yakoub-Agha, Ibrahim ;

Nagler, Arnon .

BONE MARROW TRANSPLANTATION, 2020, 55 (08) :1525-1532

← 1 2 3 4 5 6 7 8 9 10 →